3 Much attention has therefore been focused on whether noninvasive methods can detect clinically significant steatosis, fibrosis, or cirrhosis or can discriminate between simple steatosis and NASH in NAFLD patients.4-6 Several imaging techniques may be used to detect steatosis but are not sufficient to stage liver fibrosis. In addition, several markers including extracellular matrix components or enzymes involved in their degradation or synthesis have been described to predict the degree of fibrosis.7, 8 However, the utility of these markers as predictors of liver damage is limited and controversial. Clinical decision making often requires differentiation of minimal from intermediate stages

of fibrosis. The inability of serological fibrosis markers to correctly identify patients with intermediate fibrosis stages has been suggested to be 30%-70%.9 Small molecule library solubility dmso For instance, a combination of different parameters involved in fibrogenesis was shown learn more to accurately detect fibrosis, but the discriminative power between early fibrosis stages was limited.10, 11 Thus, there is an urgent need to develop simple, noninvasive tests that can identify the stage of liver disease and

accurately distinguish NASH from simple steatosis. Increasing evidence suggests an important role for hepatocyte apoptosis in the progression of NALFD and other liver diseases.12, 13 During apoptosis, caspases are activated and cleave various substrates, including cytokeratin-18 (CK-18), a major intermediate filament protein in hepatocytes.14, 15 Apoptosis of hepatocytes is further associated with the release of caspase-cleaved CK18 fragments in the bloodstream. CK-18 cleavage generates

a neoepitope that can be detected by the monoclonal antibody M30 and therefore allows the assessment of apoptosis specifically of epithelial cells by an enzyme-linked immunosorbent assay (ELISA). In contrast, another assay, the M65 ELISA, detects both caspase-cleaved and uncleaved CK-18 and is therefore used as a marker of overall death including apoptosis and necrosis. Using the M30 antibody, we initially demonstrated that CK-18 cleavage and apoptosis are increased in liver tissue of patients with various liver diseases.16, 17 Moreover, we could detect a caspase-generated CK-18 fragment in sera of patients with liver disease but selleck products not in healthy individuals.18 Subsequently, we and others demonstrated that caspase-generated CK-18 fragments are increased in sera of patients with various acute or chronic liver diseases.19-23 Furthermore, it was recently shown that the plasma concentration of the CK-18 fragments accurately differentiated NASH from NAFL.24-26 These results therefore suggest a potential use of CK18 fragments as a biomarker for the staging of chronic liver disease. Whether apoptosis is the sole cell death mechanism involved in liver diseases is currently unknown.